Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Sergiusz Nawrocki
Based on 3 articles published since 2009
(Why 3 articles?)

Between 2009 and 2019, Sergiusz Nawrocki wrote the following 3 articles about Pancreatic Neoplasms.
+ Citations + Abstracts
1 Guideline Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours). 2017

Kos-Kudła, Beata / Blicharz-Dorniak, Jolanta / Strzelczyk, Janusz / Bałdys-Waligórska, Agata / Bednarczuk, Tomasz / Bolanowski, Marek / Boratyn-Nowicka, Agnieszka / Borowska, Małgorzata / Cichocki, Andrzej / Ćwikła, Jarosław B / Falconi, Massimo / Foltyn, Wanda / Handkiewicz-Junak, Daria / Hubalewska-Dydejczyk, Alicja / Jarząb, Barbara / Junik, Roman / Kajdaniuk, Dariusz / Kamiński, Grzegorz / Kolasińska-Ćwikła, Agnieszka / Kowalska, Aldona / Król, Robert / Królicki, Leszek / Krzakowski, Maciej / Kunikowska, Jolanta / Kuśnierz, Katarzyna / Lampe, Paweł / Lange, Dariusz / Lewczuk-Myślicka, Anna / Lewiński, Andrzej / Lipiński, Michał / Londzin-Olesik, Magdalena / Marek, Bogdan / Nasierowska-Guttmejer, Anna / Nawrocki, Sergiusz / Nowakowska-Duława, Ewa / Pilch-Kowalczyk, Joanna / Rosiek, Violetta / Ruchała, Marek / Siemińska, Lucyna / Sowa-Staszczak, Anna / Starzyńska, Teresa / Steinhof-Radwańska, Katarzyna / Sworczak, Krzysztof / Syrenicz, Anhelli / Szawłowski, Andrzej / Szczepkowski, Marek / Wachuła, Ewa / Zajęcki, Wojciech / Zemczak, Anna / Zgliczyński, Wojciech / Zieniewicz, Krzysztof. ·Klinika Endokrynologii i Nowotworów Neuroendokrynnych, Katedra Patofizjologii i Endokrynologii, Śląski Uniwersytet Medyczny. endoklin@sum.edu.pl. ·Endokrynol Pol · Pubmed #28597909.

ABSTRACT: Progress in the diagnostics and therapy of gastro-entero-pancreatic (GEP) neuroendocrine neoplasms (NEN), the published results of new randomised clinical trials, and the new guidelines issued by the European Neuroendocrine Tumour Society (ENETS) have led the Polish Network of Neuroendocrine Tumours to update the 2013 guidelines regarding management of these neoplasms. We present the general recommendations for the management of NENs, developed by experts during the Third Round Table Conference - Diagnostics and therapy of gastro-entero-pancreatic neuroendocrine neoplasms: Polish recommendations in view of current European recommenda-tions, which took place in December 2016 in Żelechów near Warsaw. Drawing from the extensive experience of centres dealing with this type of neoplasms, we hope that we have managed to develop the optimal management system, applying the most recent achievements in the field of medicine, for these patients, and that it can be implemented effectively in Poland. These management guidelines have been arranged in the following order: gastric and duodenal NENs (including gastrinoma); pancreatic NENs; NENs of the small intestine and appendix, and colorectal NENs.

2 Review Primarily resectable pancreatic adenocarcinoma - to operate or to refer the patient to an oncologist? 2019

Piątek, Michał / Kuśnierz, Katarzyna / Bieńkowski, Michał / Pęksa, Rafał / Kowalczyk, Marek / Nawrocki, Sergiusz. ·Department of Oncology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland. · Department of Gastrointestinal Surgery, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland. · Department of Patomorphology, Medical University of Gdańsk, Poland. Electronic address: michal.bienkowski@gumed.edu.pl. · Department of Patomorphology, Medical University of Gdańsk, Poland. · Department of Radiotherapy, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland. ·Crit Rev Oncol Hematol · Pubmed #30819452.

ABSTRACT: The aim of this work is to investigate the optimal therapeutic sequence of resectable pancreatic cancer - primary surgery with adjuvant therapy or neoadjuvant followed by resection. Application of the neoadjuvant approach in routine treatment of pancreatic cancer is rapidly growing every year, despite the lack of final results from randomized trials. Recent advancements in the adjuvant therapy, due to the more effective chemotherapy regimens, favor the upfront surgery strategy. On the other hand, theoretical background and metaanalyses favor the neoadjuvant strategy. Currently, primary resection with adjuvant chemotherapy remains the standard approach in resectable pancreatic cancer, but the first recommendations considering the neoadjuvant approach as an option seem to arise among the scientific societies with a global impact. Preliminary results of Prodige 24 study and PREOPANC-1 trial demonstrates that both options are worth further evaluation in clinical trials. Their results should soon provide more answers to this important clinical questions.

3 Article Assessment of the safety and efficiency of sunitinib malate in metastatic neuroendocrine tumours of the pancreas (NEN G1/G2) depending on the number and type of earlier therapeutic lines - initial report. 2014

Wachuła, Ewa / Ćwikła, Jarosław B / Rogowski, Wojciech / Boratyn-Nowicka, Agnieszka / Szabłowska-Siwik, Sylwia / Piątek, Michał / Zemczak, Anna / Michalik, Barbara / Jarząb, Barbara / Nawrocki, Sergiusz / Kos-Kudła, Beata. ·Division of Radiotherapy and Oncology, Department of Clinical Oncology, Silesian Medical University, Katowice, Poland. e.wachula@wp.pl. ·Endokrynol Pol · Pubmed #25554616.

ABSTRACT: INTRODUCTION: The objective of this paper was to assess the safety and efficacy of sunitinib malate in patients with well-differentiated metastatic pancreatic neuroendocrine neoplasms (PNENs) who relapsed on standard therapy. MATERIAL AND METHODS: Overall, eight patients with well-differentiated pancreatic neuroendocrine tumours/neoplasm (NET/NEN G1/G2, Ki-67 < 20%), who had relapsed on a standard therapy approach, were treated. All had non-resectable, progressive disease. All received therapy using a standard dose of sunitinib malate. Adverse events were evaluated using NCI-CTC AE v. 3.0. RESULTS: Of the eight patients, seven had non-secretor and single secretor tumour (gastrinoma). Partial remission (PR) was noted in three patients (one after a single therapeutic line, two after two lines), five patients had stabilisation (SD) - including three individuals after three lines, one patient after two lines and another after a single line. Haematological adverse events: leukopenia (25%) - occurred in one patient after three lines and in one patient after two lines; anaemia (25%) - in one patient after three lines and in one patient after one therapeutic line. Mucocutaneous lesions were noted in 37.5% of patients after 2-3 lines of treatment. All of them experienced fatigue syndrome irrespective of the number of therapies. The majority of the patients simultaneously received somatostatin analogues, which did not exacerbate the toxicity profile. The median progression-free survival time (PFS) was 11 months. CONCLUSIONS: Sunitinib may be considered as a fairly well-tolerated and effective therapeutic option in progressive non-resectable PNEN patients in the second and subsequent lines of treatment, irrespective of the types of treatment previously applied.